Listar por autor "Wedemeyer, H."
Mostrando ítems 1-17 de 17
-
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment
Mederacke, I.; Yurdaydin, C.; Dalekos, G. N.; Bremer, B.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Bozkaya, H.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H.; Hep-Net Int Delta Hepatitis, Study (2012)Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected ... -
ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT
Mederacke, I.; Yurdaydin, C.; Bremer, B.; Cakaloglu, Y.; Erhardt, A.; Yalcin, K.; Zachou, K.; Gurel, S.; Heidrich, B.; Dalekos, G.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H. (2010) -
Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters?
Onder, F. O.; Erhardt, A.; Idilman, R.; Keskin, O.; Dalekos, G. N.; Yalcin, K.; Manns, M. P.; Wedemeyer, H.; Yurdaydin, C. (2012) -
Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV
Fytili, P.; Dalekos, G.; Cornberg, M.; Schlaphoff, V.; Zauner, W.; Zachou, K.; Manus, M. P.; Klade, C.; Wedemeyer, H. (2006) -
Cross-genotype-reactivity of the immunodominant HCVCD8 T-cell epitope NS3-1073
Fytili, P.; Dalekos, G. N.; Schlaphoff, V.; Suneetha, P. V.; Sarrazin, C.; Zauner, W.; Zachou, K.; Berg, T.; Manns, M. P.; Klade, C. S.; Cornberg, M.; Wedemeyer, H. (2008)The HCV-specific HLA-A2-restricted NS3(1073) epitope is one of the most frequently recognized epitopes in hepatitis C. NS3(1073)-specific T-cell responses are associated with clearance of acute HCV-infection. Therefore ... -
EFFICACY OF PEGYLATED INTERFERON-BASED TREATMENT IN PATIENTS WITH CIRRHOSIS DUE TO CHRONIC DELTA HEPATITIS: COMPARISON WITH NON-CIRRHOTIC PATIENTS
Yurdaydin, C.; Kobacam, G.; Cakaloglu, Y.; Erhardt, A.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Dalekos, G. N.; Bozkaya, H.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H. (2009) -
HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome
Heidrich, B.; C. Serrano, B.; Idilman, R.; Kabaçam, G.; Bremer, B.; Raupach, R.; Önder, F. O.; Deterding, K.; Zacher, B. J.; Taranta, A.; Bozkaya, H.; Zachou, K.; Tillmann, H. L.; Bozdayi, A. M.; Manns, M. P.; Yurdaydin, C.; Wedemeyer, H. (2012)Background and Aims: The presence of the hepatitis B virus (HBV)-eAg in patients with hepatitis B is associated with higher HBV replication and with an increased risk to develop liver-related clinical endpoints defined as ... -
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment
Grabowski, J.; Yurdaydìn, C.; Zachou, K.; Buggisch, P.; Hofmann, W. P.; Jaroszewicz, J.; Schlaphoff, V.; Manns, M. P.; Cornberg, M.; Wedemeyer, H. (2011)Background: Hepatitis delta is caused by infection with the hepatitis D virus (HDV) and is considered the most severe form of viral hepatitis. Treatment options for hepatitis delta are limited, with only 25% of patients ... -
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ... -
LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA
Heidrich, B.; Yurdaydin, C.; Kabacam, G.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Bock, T.; Idilman, R.; Manns, M. P.; Wedemeyer, H. (2013) -
Long-Term HDV-RNA Suppression - HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy
Niro, G. A.; Smedile, A.; Fontana, R.; Olivero, A.; Ciancio, A.; Pittalunga, F.; Coppola, N.; Wedemeyer, H.; Zachou, K.; Marrone, A.; Fasano, M.; Santantonio, T.; Lotti, G.; Andriulli, A.; Rizzetto, M. (2014) -
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis
Kabacam, G.; Dalekos, G. N.; Cakaloglu, Y.; Zachou, K.; Bock, T.; Erhardt, A.; Zeuzem, S.; Tabak, F.; Yalcin, K.; Bozdayi, A. M.; Dienes, H. P.; Bozkaya, H.; Manns, M.; Wedemeyer, H.; Yurdaydin, C. (2012)Background/aims: The safety and efficacy of interferons in advanced delta hepatitis have not been explored. The aim of this subanalysis of a multi-center clinical trial was to compare the efficacy and safety of 48 weeks ... -
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis
Zachou, K.; Yurdaydin, C.; Drebber, U.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Schlaphoff, V.; Dienes, H. P.; Bock, T. C.; Manns, M. P.; Wedemeyer, H. (2010)Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ... -
Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection
Mederacke, I.; Yurdaydin, C.; Großhennig, A.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Chatzikyrkou, C.; Bozkaya, H.; Dalekos, G. N.; Manns, M. P.; Wedemeyer, H. (2012)Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available ... -
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta
Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ... -
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience
Tillmann, H. L.; Hadem, J.; Leifeld, L.; Zachou, K.; Canbay, A.; Eisenbach, C.; Graziadei, I.; Encke, J.; Schmidt, H.; Vogel, W.; Schneider, A.; Spengler, U.; Gerken, G.; Dalekos, G. N.; Wedemeyer, H.; Manns, M. P. (2006)Acute hepatitis B progresses to liver failure with the need of liver transplantation in about 1% of cases. We treated patients with severe acute or fulminant hepatitis B with lamivudine in an attempt to prevent hepatitis ... -
Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the HEP-NET/International HDV Intervention Trial
Zachou, K.; Yurdaydin, C.; Dienes, H. R.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Bock, T.; Schlaphoff, V.; Manns, M. R.; Wedemeyer, H. (2006)